Background {#Sec1}
==========

Renal cell carcinoma (RCC) is a relatively common malignancy accounting for approximately 2 % of all adult cancers and causing approximately 100,000 deaths per year worldwide \[[@CR1]\]. 80 % of renal cell carcinoma (RCC) cases are classified as clear cell renal cell carcinoma (ccRCC), originated from proximal convoluted tubule, with annually 168,000 newly diagnosed cases \[[@CR2]\]. During last 30 years the incidence of RCC has been steadily increasing, likely due to the higher exposition to risk factors such as cigarette smoking, obesity, hypertension and accidental diagnosis due to improved visualization techniques \[[@CR3]\].

Familial, associated with von Hippel-Lindau (VHL) syndrome, and sporadic ccRCC have been linked to inactivation of *VHL* gene by mutation, loss of heterozygosity (LOH) and promoter hypermethylation \[[@CR4]--[@CR6]\]. *VHL* inactivation is the most established cause of ccRCC, but there are several other factors involved in pathogenesis of tumor type exemplified by mutations in *KNG1* and *MT1A* genes \[[@CR7]\], as well as PI3K/AKT/mTOR signaling pathway factors (*MTOR*, *PTEN*, *PIK3CA)* \[[@CR8]\].

One group of ccRCC deregulated genes contains gene transcripts belonging to TMEM (transmembrane proteins) gene family. Differential regulation of TMEMs could be observed in many cancers, such as lymphomas (*TMEM176*) \[[@CR9]\], colorectal cancer (*TMEM25*) \[[@CR10]\], meningiomas (*TMEM30B*) \[[@CR11]\], paragangliomas and pheochromocytomas (*TMEM127*) \[[@CR12]\]. In case of ccRCC, up- or down-regulation of different TMEMs is supported by a number of microarray experiments \[[@CR13]--[@CR19]\].

In our recently published microarray-based meta-analysis, we identified a number of up- and down-regulated genes with limited information available concerning their biological role. We found 10 significantly deregulated genes (8 down- and 2 up-regulated) which were represented by gene transcripts belonging to TMEM gene family, with highest down-regulation of *TMEM213* (effect size = −11.7) and highest up-regulation of *TMEM45A* (effect size = 2.6) \[[@CR20]\]. TMEMs are a group of ca. 310 different proteins (with ca. 440 identified isoforms and ca. 580 transcript variants) predicted to be components of cellular membranes, such as mitochondrial membranes, lysosomes and Golgi apparatus. Interestingly, the function of majority of TMEM proteins remains unclear, mainly due to difficulties in extraction and purification of transmembrane proteins. Nevertheless many TMEM proteins have been functionally assigned as trans-membranous anion channels (e.g., ANO1) \[[@CR21]\] and molecules responsible for oncosis (TMEM123) \[[@CR22]\], protein glycosylation (TMEM165) \[[@CR23]\], pathogen intoxication (TMEM181) \[[@CR24]\], as well as innate immunity response (TMEM173) \[[@CR25]\]. Although down-regulation of TMEMs has been detected in large number of microarrays on ccRCC tumors, not much is known about their function in pathogenesis of ccRCC.

Research performed by Kholodnyuk *et al.* showed that *RTP3* (*TMEM7*) expression in 5 different RCC cell lines - KH39, CAKI-1, CAKI-2, KRC/Y and TK-10 was impaired in comparison to normal human kidney by RT-PCR \[[@CR26]\] and was suggested to act as of tumor suppressor gene. Additionally, overexpression of *SLC35G2* (*TMEM22*) and *RAB37* genes in ccRCC tumors was observed \[[@CR27], [@CR28]\] and experiments on RCC cell lines implied that the SLC35G2/RAB37 complex was likely to play a crucial role in growth of RCC \[[@CR29]\].

Here we compared expression of 10 TMEM family members: *RTP3*, *SLC35G2*, *TMEM30B*, *TMEM45A*, *TMEM45B*, *TMEM61*, *TMEM72*, *TMEM116*, *TMEM207* and *TMEM213* in tumors histopathologically classified as ccRCC. Additionally, we correlated expression of these genes with *VHL*, *HIF1A* and *EPAS1* expression. We also analyzed expression of 10 TMEM genes in PBMCs of patients with metastatic and non-metastatic ccRCC, at the time of nephrectomy and a year post-nephrectomy. Moreover, we tested if expression of TMEM could be utilized as a potential predictor for metastases, progression-free disease course and patient survival rate. Lastly, we tried to predict topology and tertiary structure of TMEMs using bioinformatic tools.

Methods {#Sec2}
=======

Patient material collection {#Sec3}
---------------------------

The samples were obtained prospectively from 76 histopathologically confirmed ccRCC tumors (Additional file [1](#MOESM1){ref-type="media"}: Table S2). Collected tissue represented cross-section of kidney tissue (i.e., inner tumor mass, border of a tumor and non-tumoral kidney tissue). Analyzed tissue represented inner but not necrotic tumor tissue. Tissues were suspended in RNALater® reagent (Sigma-Aldrich, St. Louis, MO, USA). Peripheral blood from ccRCC patients was collected before nephrectomy and ca. a year post surgery (Additional file [2](#MOESM2){ref-type="media"}: Table S3). Mean time of a follow-up was equal to 13.31 months, with median 12.5 months and range 3--34 months. Tissues and PBMCs (Peripheral Blood Mononuclear Cells) samples were obtained from the Department of Urology and Urological Oncology, Poznan University of Medical Sciences. This research was approved by Local Bioethical Committee at Poznan University of Medical Sciences (Poland), no. 1124/12 and written informed consent to participate in the study and to publish individual clinical data (including age and gender) was obtained from all patients. Disease progression was defined as local neoplasm recurrence or distant metastasis detected by at least one of following methods: X-ray, abdominal ultrasound and computer tomography of chest and abdomen. Detailed patient clinical characteristics are presented in Table [1](#Tab1){ref-type="table"}.Table 1Characterization of ccRCC patient cohort. Median age of healthy donors which PBMCs were obtained from was 42.50 years old, 25 % Percentile = 35, 75 % Percentile = 46.75. Abbreviations: NM -- not measuredName of the characteristicAmountTumor tissuePBMCs before nephrectomyPBMCs 12 months post-nephrectomyNumber of samples included in the studyPatients766627Controls231414GenderMales (%)45 (59)45 (68)19 (70)Females (%)31 (41)21 (32)8 (30)Age (at a time of surgery)Median64656125 % Percentile57565375 % Percentile727369Tumor size \[mm\]Median4343.504425 % Percentile3331.8828.5075 % Percentile65.386559TNM stage -- pTpT1 (%)40 (52)34 (51)16 (59)pT2 (%)2 (3)3 (5)2 (8)pT3 (%)32 (42)28 (42)9 (33)pT4 (%)2 (3)1 (2)0 (0)TNM stage -- pNpN0 (%)73 (96)63 (95)27 (100)pN1 (%)3 (4)3 (5)0TNM stage -- MM0 (%)62 (82)52 (79)25 (93)M1 (%)14 (18)14 (21)2 (7)Fuhrman gradeG1 (%)4 (6)4 (6)0 (0)G2 (%)35 (46)32 (48)17 (63)G3 (%)26 (34)22 (33)9 (33)G4 (%)11 (14)8 (13)1 (4)VHL expressionVHL+33NMNMVHL-43NMNM

RNA isolation from tissues and PBMCs {#Sec4}
------------------------------------

Tissue total RNA was isolated from homogenized tumor tissue using GeneMATRIX Universal RNA Purification Kit (EurX, Gdańsk, Poland) following supplied protocol. PBMC RNA was isolated using Ficoll gradient (GE Healthcare, Little Chalfont, Buckinghamshire, England) followed by RNA extraction using TRI Reagent® (Molecular Research Center, Cincinnati, OH, USA). RNA quality and quantity was determined with NanoDrop Spectrophotometer ND-1000 (Thermo Scientific, Wilmington, DE, USA).

Reverse transcription and real-time PCR {#Sec5}
---------------------------------------

1 μg of RNA was reversely transcribed using RevertAid™ First Strand cDNA Synthesis Kit with Random Hexamers (Thermo Scientific Fermentas, Waltham, MA, USA) following supplied protocol.

Analyses were performed using Eco Real Time System (Illumina, San Diego, CA, USA), with Maxima™ SYBR Green/ROX qPCR Master Mix (2×) (Thermo Scientific Fermentas, Waltham, MA, USA) following supplied protocol. Primers were designed using Primer-BLAST (<http://www.ncbi.nlm.nih.gov/tools/primer-blast>) and Oligo Analyzer 3.1 (<http://eu.idtdna.com/analyzer/applications/oligoanalyzer/default.aspx>). Analyzed samples were corrected by reaction efficiency obtained from standard curves which varied from 91 % to 110 %. Primers used for the analyses are listed in Additional file [3](#MOESM3){ref-type="media"}: Table S1. Expression of each gene in ccRCC tissue samples and PBMCs was measured in duplicates, in two independent experiments. Calculated normalized relative quantities (CNRQ) of transcripts were obtained by normalization to reference gene (*ACTB*) and average of reference samples using qBase Plus software (<https://www.biogazelle.com/qbaseplus>).

Statistical analysis {#Sec6}
--------------------

All charts were prepared using GraphPad Prism software v6.02 ([http://www.graphpad.com](http://www.graphpad.com/)). IBM SPSS Statistics software v22 (<http://www-01.ibm.com/software/analytics/spss/products/statistics/>) was used for *t*-test, ANOVA and Pearson correlations. For clusters analysis TMEM expression values were dummy-coded basing on their deviation from average expression among all tumor samples. Univariate and multivariate logistic regression, and univariate and multivariate Cox regression were performed using R statistical software v3.1.1 \[[@CR30]\]. For regression models, AIC (Akaike information criterion) \[[@CR31]\] was used to assess the relative quality of each predictor, as compared to the null model. Firstly, in case of multivariate logistic regression, maximum 4 best predictors was chosen (to prevent a model from overfitting) based on best subset selection using *leaps* package \[[@CR32]\] and the lasso shrinkage method using *glmnet* package \[[@CR33], [@CR34]\]. Each variable were tested for colinearity using variance inflation factor (VIF) calculation \[[@CR35]\]. Then, each coefficient was recalculated using penalized maximum likelihood estimation to avoid overfitting of a model by *rms* package \[[@CR36]--[@CR40]\]. To assess true standard error and prediction capabilities of each model bootstrap and cross-validation methods were used, as implemented in *rms* library \[[@CR37]\]. Univariate Cox regression to assess the marginal effect of each factor (when not correcting for the effect of other factors) were performed. Multivariate Cox regression was calculated by *rms* package and variables in the model were included based on step-wise method and the lasso shrinkage method using *glmnet* package \[[@CR41]\]. Each variable included in Cox regression model was tested for proportional hazards assumption based on Grambsch and Therneau method \[[@CR42]\]. All p-values obtained during statistical analyses (i.e., from t-tests, ANOVA, Pearson correlations, univariate and multivariate logistic and Cox regression models) were adjusted all together for multiple comparisons using Benjamini-Hochberg method \[[@CR43]\], and obtained q-values were considered to be statistically significant at q ≤ 0.1.

Bioinformatic prediction of TMEMs topology and function {#Sec7}
-------------------------------------------------------

*Query sequences selection*: The following NCBI RefSeq sequences of native human TMEMs were used for bioinformatics analysis, NCBI GIs: 146229352 (TMEM213), 46409276 (TMEM207), 32698902 (TMEM61), 20270331 (TMEM45B), 63003930 (TMEM30B), 13899263 (RTP3), 183227675 (TMEM72), 302058299 (TMEM116), 148224156 (SLC35G2) and 8922243 (TMEM45A). *Pfam analysis*: Query sequences were submitted to the Pfam 27.0 database of protein families and Hidden Markov model HMM searches (default Pfam-A data set and e-value of 1.0) were conducted \[[@CR44]\]. *Fold recognition analysis Metaserver*: Full-length sequences were submitted to Genesilico Metaserver gateway \[[@CR45]\]. The consensus of different programs and servers was used to determine transmembrane helices, protein order and secondary structure, using 12, 16 and 17 methods, respectively. Protein solvation prediction was determined with 6 different programs and relative solvent accessibility of amino acid (RSA, %). An aa was considered buried with RSA value lower than a assumed, implemented threshold (25 %, 5 %, or 0 %). If RSA value for the aa was higher than the threshold, it was considered as exposed. TMEM homologs with tertiary structures deposited in RCSB PDB were determined by fold-recognition methods, which were compared, evaluated, and ranked by the Pcons5 algorithm \[[@CR46]\]. *[PSORT II:]{.ul}* Sequences were submitted and analyzed based on their amino acid sequence \[[@CR47]\]. The presence of signal sequences was determined by recognizing positively charged N-region, the central hydrophobic region and searching the position of possible cleavage site \[[@CR48], [@CR49]\]. TM segments were predicted with ALOM method and the membrane topology was scored using Singer's classification \[[@CR50], [@CR51]\]. The cytoplasmic/nuclear discrimination for TMEMs was analyzed by Reinhardt's algorithm, which determines the probability of protein localization by \`NNCN score\` \[[@CR52]\]. *[Localization assignment]{.ul}*: mitochondrial \[[@CR47]\], nuclear \[[@CR52]\], peroxisomal \[[@CR53]\], endoplasmic reticulum \[[@CR54]\], lysosomal and vacuolar \[[@CR55]\] were presented as consensus with the use of k-nearest neighbor (k-NN) algorithm \[[@CR56]\]. *[Localizome]{.ul}*: TM helix number and topology was predicted with Phobius algorithm \[[@CR57], [@CR58]\]. The hmmpfam method was employed (default e-value of 0.01) to include domains obtained from Pfam. Combined results were validated by LocaloDom database of protein domains. *[Consensus analysis]{.ul}*: Metaserver, PSORT II and Localizome predictions of TMEMs were superimposed. Obtained colocalization of the data was analyzed to find the most probable protein topology and evaluate the reliability of the calculations.

Results {#Sec8}
=======

TMEM expression in tumor tissue {#Sec9}
-------------------------------

In line with our previous observations, we detected statistically significant differences in expression of all ten TMEMs in tumor tissue and healthy kidney tissue (Fig. [1a](#Fig1){ref-type="fig"}) \[[@CR20]\]. The down-regulation varied between the genes, with 1758.34 fold for *TMEM213* (q \< 0.0001) and 3.06 fold for *TMEM116* (q \< 0.05). Both, *SLC35G2* and *TMEM45A* were found to be up-regulated with 5.33 (q \< 0.01) and 6.75 fold change (q \< 0.0001), respectively. We investigated if analyzed TMEMs displayed differential expression in metastatic and non-metastatic tumors. As shown in Fig. [1b](#Fig1){ref-type="fig"}, we detected significant difference in expression of *TMEM72* and *TMEM116*: 39.78 fold and 6.65 fold down-regulation in metastatic tissue (*n* = 12 and *n* = 14, respectively) as compared to 5.13 fold and 2.57 fold in the non-metastatic samples (*n* = 58, q = 0.051 and *n* = 62, q = 0.056, respectively). Next, we subdivided samples into organ-confined tumors (pT ≤ 2) and advanced tumors (pT ≥ 3). A decrease of *TMEM30B* (q = 0.106) and *TMEM45B* (q = 0.097) expression was found in advanced-stage samples, with −2.21 and −2.71 fold-change, as compared to early-stage tumors, respectively (Fig. [1c](#Fig1){ref-type="fig"}). T-test was used to compare TMEM expression in well differentiated tumors (Fuhrman grade, G ≤ 2) with undifferentiated tissues (G ≥ 3, Fig. [1d](#Fig1){ref-type="fig"}) and we observed a stronger down-regulation of *TMEM30B* in high Fuhrman grade samples (fold-change −31.18, *n* = 36) in contrast to low Fuhrman grade samples (fold-change −12.29, *n* = 39, q \< 0.05). Expression comparisons of all analyzed 10 TMEM genes in metastatic and non-metastatic tumors, early- and late stage samples, and tumors with undifferentiated and well-differentiated tissues are shown in Additional file [4](#MOESM4){ref-type="media"}, [5](#MOESM5){ref-type="media"} and [6](#MOESM6){ref-type="media"}: Figures S1-S3, respectively.Fig. 1Differential expression of TMEMs in tumor tissue. (**a**) A comparison of TMEM expression between a tumor tissue and healthy kidney tissue. (**b**) TMEM expression in metastatic and non-metastatic tumors. (**c**) TMEM expression in organ-confined and advanced stage tumors (**d**) TMEM expression in low Fuhrman grade and high Fuhrman grade samples. Average log~2~ relative expression data in each sample group ± standard error of mean is shown in each chart. FC -- fold-change. n -- number of samples. T -- tumor tissue samples. C -- healthy tissue samples. M0 -- non-metastatic ccRCC. M1 -- metastatic ccRCC tissues. pT1/pT2 -- organ-confined tumors, as assessed by TNM staging system. pT3/pT4 -- advanced tumors, as assessed by TNM staging system. G1/G2 -- low Fuhrman grade samples. G3/G4 -- high Furhman grade samples. \* - q \< 0.05. \*\* - q \< 0.01. \*\*\* - q \< 0.001. \*\*\*\* - q \< 0.0001

Pearson correlation of TMEMs and *VHL*, *HIF1A* and *EPAS1* expression values was performed but correlation coefficient did not exceed 0.55 (in case of *EPAS1* expression correlated with *SLC35G2* (r = 0.55), *TMEM30B* (r = 0.32), *TMEM72* (r = 0.44) and *TMEM116* (r = 0.35), data not shown). Finally, we correlated TMEM expression between each other and overall we found the highest statistically significant Pearson correlation coefficient in case of *TMEM213* with *TMEM30B* (Fig. [2a](#Fig2){ref-type="fig"}) and for *TMEM72* correlated with *TMEM116* (Fig. [2b](#Fig2){ref-type="fig"}).Fig. 2Correlations for the expression of TMEM genes in tumor tissue. (**a**) Pearson correlation between the expression of *TMEM30B* and *TMEM213*. (**b**) Pearson correlation between the expression of *TMEM72* and *TMEM116*. r -- Pearson correlation coefficient. q -- q-value, n -- number of samples

In attempt to stratify the ccRCC tumors and to establish common expression profile based on TMEM expression we performed hierarchical clustering of available data (Fig. [3](#Fig3){ref-type="fig"}). TMEM expression values were dummy-coded basing on their deviation from average expression among all tumor samples as samples with TMEM expression above average (coded as "+1") and below average (coded as "-1"). Using IBM SPSS Statistics v22 software we identified five distinctive tumor clusters. Cluster I was characterized by low expression of *TMEM72*, *TMEM116*, *TMEM207* and *TMEM213*. Samples with low expression of *RTP3*, *TMEM207* and *TMEM213* and with high expression of *SLC35G2*, *TMEM72* and *TMEM116* were preferentially assigned to cluster II. In cluster III low expression of *TMEM45A* and *TMEM72*, and high expression of *TMEM61* were observed. Low expression of *TMEM30B*, *TMEM207* and high expression of *RTP3*, *TMEM45A* and *TMEM116* were distinctive for cluster IV. Cluster V was characterized by high expression of *TMEM30B*, *TMEM45B* and *TMEM213*. Interestingly, cluster I was overrepresented by samples with more advanced disease stage (*n* = 21), as measured by tumor stage (TNM scale), Fuhrman grade and metastasis and cluster V contained less advanced tumors.Fig. 3A dendrogram of hierarchical clustering of tumor samples based on TMEMs expression with denoted clusters. Clinical characteristics of samples: M -- distant metastases status (0 -- no distant metastases; 1 -- distant metastases at the time of nephrectomy). pT -- tumor size (TNM scale). Expression status of TMEM genes depicted as below average (−1) and above average (1)

TMEM expression in tumor tissue as independent predictors of metastases, Fuhrman grade and disease progression {#Sec10}
--------------------------------------------------------------------------------------------------------------

We checked TMEM expression in subgroups divided according to clinical parameters (i.e., gender, smoking status, hypertension etc.) and analyzed TMEM correlation with continuous variables, such as age, average tumor size etc., but we did not find any significant differences (data not shown).

To evaluate the independent prediction of TMEM expression for clinical parameters univariate and multivariate logistic regression analyses were implemented (Table [2](#Tab2){ref-type="table"}).Table 2Univariate and multivariate logistic regression analysis with clinical parameters and profiles of TMEM expression in tumors. (A) metastatic and non-metastatic samples. (B) Low and high Fuhrman grade samples. Confidence intervals and p-values in multivariate logistic regression were calculated using 10000-times bootstrap and were reported for penalized model. ROC AUC and R^2^ parameters from both bootstrap and cross-validation were reported. *Abbreviations:* OR -- odds ratio. 95 % CI OR -- 95 % confidence interval. AIC -- Akaike Information Criterion. n -- number of samples. ROC AUC -- receiver operating characteristics area under curve parameter. VIF -- variance inflation factor(A) MetastasesUnivariateMultivariate*p*-valueq-valueOR95%CI ORAIC*np*-valueq-valueOR95%CI ORAIC*n*VIFROC AUCR^2^ROC AUCR^2^LowerUpperLowerUpperBootstrapCross-validationAverage tumor size \[mm\]0.00010.0041.0701.0381.11353.46760.00020.0061.0871.0511.16238.09701.1950.9190.5650.9320.800*TMEM72* expression0.0090.0890.7760.6340.93160.67700.01130.1050.7380.5550.8841.195Symptoms0.0020.0327.5002.19928.51166.1976Variables not in the multivariate model*TMEM116* expression0.0090.0940.6010.3940.86368.8476*TMEM61* expression0.0190.1390.7900.6340.94560.4468*EPAS1* expression0.1020.3660.6840.4281.07973.9376(B) Fuhrman gradeUnivariateMultivariate*p*-valueq-valueOR95%CI ORAIC*n*p-valueq-valueOR95%CI ORAIC*n*VIFROC AUCR^2^ROC AUCR^2^LowerUpperLowerUpperBootstrapCross-validation*EPAS1* expression0.000040.0020.2350.1070.43378.70760.00030.0080.2650.1170.47662.80751.1430.8980.6000.9190.798Smoking0.001770.0184.7641.83713.15398.75760.07720.3173.0920.95412.6161.069Average tumor size \[mm\]0.002990.0321.0391.0151.06798.11760.0040.0541.0481.0231.0991.241*TMEM30B* expression0.005740.0440.6450.4600.85897.98750.020.1460.6340.3510.8251.286*VHL* expression0.02080.0660.5290.2950.882103.2176Variables not in the multivariate model*TMEM72* expression0.02550.1500.8320.6990.97095.2270*TMEM45B* expression0.0280.1670.7940.6370.966103.9276*TMEM116* expression0.04080.1800.7250.5200.970104.5876*SLC35G2* expression0.04420.2220.8110.6510.985103.3875

To evaluate differential TMEM expression as potential predictor of distant metastases univariate logistic regression was performed. It revealed that, together with average tumor size, presence of symptoms, and expression of *EPAS1*, 2-fold increase in the expression of *TMEM72* and *TMEM116* decreased the odds of metastases significantly for 22 % and 40 %, respectively (Table [2A](#Tab2){ref-type="table"}). Furthermore, AIC of each TMEM predictor in univariate logistic regression was lower (60.67 and 68.84 for *TMEM72* and *TMEM116* expression respectively) than AIC of null model (AIC = 74.61) suggesting potential predicting ability of analyzed variables. Removal of each of parameters (i.e., average tumor size in mm and *TMEM72* relative expression) from multivariate model lowered the prediction ability of the model, as measured by likelihood ratio test (q \< 0.1). There were no collinear variables which could negatively influence prediction ability of the model, as assessed by VIF. The model was of good predictive ability as measured by ROC AUC values and R^2^ (ROC AUC = 0.919 and 0.932, R^2^ = 0.565 and 0.800, measured by bootstrap and cross-validation methods correspondingly).

*TMEM30B* expression could be associated with significant decrease in odds of having high Fuhrman grade tumor in univariate logistic regression analysis (Table [2B](#Tab2){ref-type="table"}). It had a potential predicting ability in case of Fuhrman grade classification, as measured by AIC (*TMEM30B* expression AIC = 97.98) compared to null model (AIC = 107.31). The multivariate logistic regression revealed that 2-fold up-regulation of *TMEM30B* could be associated with significant decrease in odds of having high Fuhrman grade tumor by 37 %, in line with univariate logistic regression. Although *TMEM30B* expression status did not reach statistical significance (q \> 0.1), removal of each parameter from the model, would worsen the model significantly, as seen using likelihood ratio test (q \< 0.1). Bootstrapped and cross-validated predictive ability of the model was very good (ROC AUC \> 0.89, R^2^ ≥ 0.6).

Univariate Cox regression (Table [3](#Tab3){ref-type="table"}) revealed that, together with other factors, 2-fold increase of *TMEM116* expression in tumor tissues is correlated with decreased risk of disease-related mortality (hazard ratio = 0.554, q = 0.086). Although hazard ratio of *TMEM72*, *SLC35G2* and *TMEM61* expression were not statistically significant, AIC for these genes were lower (AIC = 24.52, 48.63 and 32.23, respectively) than the null model (AIC = 26.35 for samples expressing *TMEM72*, AIC = 49.45 for samples expressing *SLC35G2* and AIC = 34.47 for tumors expressing *TMEM61* above detection limit). Multivariate regression model was built to assess TMEM expression as independent predictors of ccRCC-linked mortality but probably due to small sample size (total *n* = 76, cases = 7, censored = 59, no follow-up = 10) none of predictors was associated independently with this parameter (q \> 0.1). Progression-free survival was also assessed by univariate Cox regression and it revealed that expression of analyzed TMEMs could not be associated with progression-free disease course (q \> 0.1, data not shown).Table 3Univariate and multivariate overall survival Cox regression model with clinical parameters and profiles of TMEM expression in tumors. Total cases = 66, censored cases = 59. *Abbreviations:* HR -- hazard ratio. 95 % CI HR -- 95 % confidence interval. AIC -- Akaike Information Criterion. n -- number of samples. n events -- number of deaths (i.e., cases not censored). VIF -- variance inflation factorOverall survivalUnivariateMultivariate*p*-valueq-valueHR95 % CI HRAIC*n* (*n* events)*p*-valueq-valueHR95 % CI ORAIC*n* (*n* events)VIFLowerUpperLowerUpper*TMEM116* expression0.0080.0860.5540.3580.85644.8566 (7)0.0820.3197.1670.77766.14718.6061 (4)4.915Average tumor size \[mm\]0.0090.0891.0441.0111.07744.4166 (7)0.0220.1531.1331.0181.2602.788*VHL* expression0.0280.1800.5040.2730.93147.0366 (7)0.2230.5490.3790.0791.8072.430*TMEM72* expression0.0480.1860.7360.5430.99724.5261 (4)0.0450.2390.3900.1550.9803.806*SLC35G2* expression0.0670.2440.8250.6711.01448.6365 (7)Variables not in the multivariate model*TMEM61* expression0.0730.2850.7330.5221.02932.2359 (5)Symptoms0.0840.3033.7890.83417.21148.5266 (7)

TMEM expression in PBMCs of ccRCC patients {#Sec11}
------------------------------------------

To assess the utility of TMEM expression as potential biomarkers we analyzed their expression in PBMCs of ccRCC patients (see Table [1](#Tab1){ref-type="table"}). According to the Illumina Human Body Map 2.0 project (NCBI Gene Expression Omnibus accession no. GSE30611) six out of ten selected TMEMs were found to be expressed in PBMCs and those were included in further analysis (i.e., *SLC35G2*, *TMEM30B*, *TMEM45A*, *TMEM45B*, *TMEM116* and *TMEM213*). Although a comparison between expression of TMEMs in PBMCs obtained from patients before nephrectomy (T0) and from healthy volunteers did not reveal statistically significant differences, we observed significant down-regulation of *TMEM213* (fold-change = −12.24, q \< 0.0001, *n* = 17), down-regulation of *TMEM45B* (fold-change = −2.47, q \< 0.1, *n* = 26) and up-regulation of *SLC35G2* (fold-change = 2.57, q \< 0.1, *n* = 25) between PBMCs of healthy volunteers and PBMCs obtained from patients one year post nephrectomy (T2, Fig. [4](#Fig4){ref-type="fig"}). Furthermore, we found statistically significant down-regulation of *TMEM213* and up-regulation of *SLC35G2,* as comparing time points before (T0) and 12 months after the surgery (T2), suggesting fluctuation of their expression in PBMCs post-nephrectomy (Fig. [4](#Fig4){ref-type="fig"}). No correlation between TMEM expression in tumors and PBMCs was observed (data not shown). Logistic regression did not reveal the dependence of clinical parameters (i.e., tumor size, Fuhrman grade, metastases and progression status) on TMEM expression in PBMCs (data not shown). Univariate Cox regression did not suggest TMEM's expression to be involved in disease progression or survival.Fig. 4A comparison of TMEM expression in PBMCs. Average log~2~ relative expression data in each sample group ± standard error of mean is shown in each chart. FC -- fold-change. C -- control samples (PBMCs from healthy volunteers). T0 -- PBMCs obtained from patients before nephrectomy. T2 -- PBMCs obtained from patients 12 months after surgery. n -- number of samples

Bioinformatic analyses of transmembrane proteins {#Sec12}
------------------------------------------------

In order to determine the topology and structure of 10 TMEMs, found deregulated on the mRNA level in ccRCC tumors, extensive bioinformatic structural analysis was performed. Query sequences from NCBI were submitted to Pfam to classify TMEMs into known protein families \[[@CR44]\]. Moreover, three independent protein structure prediction gateways: Metaserver \[[@CR45]\], PSORT II \[[@CR47]\] and Localizome \[[@CR57]\] (Table [4](#Tab4){ref-type="table"}) were used to find consensus of the proteins topology with Pfam results.Table 4Detailed bioinformatic characteristics of TMEMs with topology and function predictions. ^1^ - Metaserver prediction. ^2^ - Localizome prediction, ^3^ - PSORT II prediction. ^4^ - Functional data available; protein localized in Golgi apparatus, endosomes and lysosomes. GI - GenInfo Identifier. TM - transmembrane helix segment. ER - endoplasmic reticulum. Mit -- mitochondrial. Nuc -- nuclear. Cyt -- cytoplasmic. n/a - no resultPropertyTMEM213TMEM207TMEM61TMEM45BTMEM30BRTP3TMEM72TMEM116SLC35G2TMEM45AFull nametransmembrane protein 213 precursortransmembrane protein 207 precursortransmembrane protein 61transmembrane protein 45Btransmembrane protein 30Breceptor-transporting protein 3transmembrane protein 72transmembrane protein 116 isoform 1solute carrier family 35 member G2transmembrane protein 45AAlternative names--UNQ846----CDC50BLTM1; TMEM7KSP37; C10orf127; bA285G1.3--TMEM22DERP7NP (NCBI)001078898.1997199.1872338.1620143.1001017970.1113628.1001116848.1001180460.1079522.2060474.1GI14622935246409276326989022027033163003930138992631832276753020582991482241568922243Protein isoforms1111111311Transcript variants1111111331Human length (aa)107146210275351232275337412275PfamTMEM213 family in eukaryotes; 154 aa; unknown functionn/aTMEM61 family in eukaryotes; 150--211 aa; unknown functionDUF716 family in metazoa (unknown function) and plants (response to viral attack)CDC50/ LEM3 (ligand-effect modulator 3) family in glucocorticoid receptor pathwayzf-3CxxC family with zinc-binding domainn/an/aEamA drug/metabolite transporter-like family with two copies of EamA domainDUF716 family in metazoa (unknown function) and plants (response to viral attack)Tertiary structure prediction^1^n/aSimilar to TM protein stannin (PDB Id: 1zza)n/an/an/aSimilar to Zn-binding proteins (PDB Id: 2cup; 2dkt; 2e2z; 3hcs)n/aSimilar to human adrenoreceptor (PDB Id: 2rh1; 2r4r) and human adenoreceptor (PDB Id: 3eml)Similar to TM domain of the multidrug-resistance antiporter from *E. coli* EmrE (PDB Id: 3b5d)n/aTM domains21121122277722211134166310108775^123^Predicted topology^3^Type 1a with cyt tail (92 to 107)Type 1a with cyt tail (71 to 146)Type 3aType 3bType 3aType Nt with cyt tail (1 to 211)Type 2 with cyt tail (1 to 94)Type 3aType 3aType 3aCleavable N-terminal signal peptide^3^Yes (1 to 27)Yes (1 to 29)NoNoNoNoNoYes (1 to 50)NoNoCytoplasmic/ Nuclear discrimination^3^Nuc (55.5)Cyt (94.1)Nuc (70.6)Cyt (94.1)Cyt (89)Cyt (89)Cyt (94.1)Cyt (94.1)Cyt (94.1)Cyt (94.1)Subcellular localization^3^ER (44.4 %)ER (44.4 %)Mit (39.1 %) Nuc (34.8 %)ER (66.7 %)ER (39.1 %) Mit (39.1 %)Cyt (30.4 %)Mit (30.4 %)ER (43.5 %)ER^4^ (55.6 %)ER (77.8 %)

TMEM213 was the most down-regulated gene of all TMEMs tested in ccRCC samples. According to Pfam database TMEM213 gene encodes a protein from the family of unknown function and average length of 154 aa, present in all eukaryotes. The Metaserver prediction suggests TMEM213 might contain two transmembrane (TM) helix segments (aa 7--26 and 71--91) with no tertiary homology to any protein crystal structures, currently available in RCSB PDB database. PSORT II classified TMEM213 as type 1a topology protein with one TM domain (aa 75--90). In contrast to Metaserver, PSORT II assigned aa 1--27 as a cleavable N-terminal signal peptide instead of TM domain (Additional file [7](#MOESM7){ref-type="media"}: Table S4). PSORT II NNCN Reinhardt's method for cytoplasmic/nuclear discrimination \[[@CR52]\] scored TMEM213 as nuclear protein with reliability of 55.5. k-NN prediction for subcellular localization \[[@CR56]\] determined TMEM213 to be connected to endoplasmic reticulum with probability of 44.4 %. Localizome analysis resulted in similar prediction to PSORT II (Fig. [5](#Fig5){ref-type="fig"}). Similar analyses were performed for the remaining 9 TMEMs as shown in Table [4](#Tab4){ref-type="table"}.Fig. 5TMEMs - prediction of orientation in plasma membrane. 'N' in red indicates N-terminus of proteins, transmembrane segments are in green, functional domains derived from Pfam database are in violet. All structures were generated using Localizome server

No Pfam results were obtained for TMEM207, TMEM72 and TMEM116. TMEM61 was assigned as a member of TMEM61 family present in eukaryotes with no known function. TMEMs 45A and 45B were found to be DUF716 (Domain of Unknown Function 716) proteins, present in all metazoa, and predicted to modulate response to viral attack in plants. TMEM30B belongs to CDC50/LEM3 (ligand-effect modulator 3) family. LEM3 affects a downstream step of the glucocorticoid receptor pathway. RTP3 (TMEM7) was predicted to contain pairs of CxxC motifs possibly representing a multiple zinc-binding region, characteristic to zf-3CxxC family. SLC35G2 (TMEM22) on the other hand was recognized as EamA drug/metabolite transporter-like family member with two copies of EamA domain also known as AMAC (acyl-malonyl condensing enzyme) transporter.

In order to confirm known homologs identified by Pfam we analyzed the protein sequences with additional fold-recognition methods available at Metaserver Genesilico gateway. TMEM213, TMEM61, TMEM45B, TMEM30B TMEM72 and TMEM45A showed no homologous crystal structures deposited in RCSB PDB. However comparison, evaluation and ranking by the Pcons5 algorithm \[[@CR46]\] at Metaserver denoted similarities of the remaining four TMEMs to known proteins. TMEM207 shared similarity with transmembrane protein stannin (PDB Id: 1ZZA), a small protein involved in inhibition of apoptosis) \[[@CR59]\]. TMEM116 was inferred similar to human adrenoreceptor (PDB Id: 2RHL and 2R4R) and human adenoreceptor (PDB Id: 3EML). Similarly to Pfam analysis RTP3 homologs were found in a heterogeneous group of Zn-binding proteins with conserved Zn-binding domain (PDB Id: 2CUP, 2DKT, 2E2Z and 3HCS) and SLC35G2 showed similarities to TM domain of the multidrug-resistance antiporter from *E. coli* EmrE (PDB Id: 3B5days) was found. For RTP3 and SLC35G2 we found confirmation of Metaserver prediction with Pfam results.

Employing Singer's classification of proteins TMEMs have been sorted according to their predicted topology \[[@CR50]\]. Majority of TMEMs are classified as type 3a transmembrane proteins (TMEM61, TMEM30B, TMEM116, SLC35G2 and TMEM45A). TMEM 45B is assigned as type 3b transmembrane protein, whereas TMEM72 -- type 2. TMEM213 and TMEM207 were grouped as type 1a with a cleavable signal sequence and one transmembrane segment. RTP3 is a protein with no cleavable signal sequence and one transmembrane segment near C-terminus (type Nt).

Subcellular localization consensus analysis at PSORT II connected TMEM213, TMEM207, TMEM45B, TMEM116, SLC35G2 and TMEM45A with endoplasmic reticulum (with reliability of 44.4 %; 44.4 %; 66.7 %; 43.5 %; 55.6 % and 77.8 %, respectively). RTP3 was found to be cytoplasmic (30.4 %) and TMEM72 -- mitochondrial (30.4 %). For TMEM61 and TMEM30B we obtained inconclusive results: mitochondrial/nuclear (39.1 %/34.8 %) and ER/mitochondrial (39.1 %/39.1 %), respectively.

Discussion {#Sec13}
==========

Recently published meta-analysis study of differentially expressed genes in ccRCC led us to examine in detail the expression of ten genes encoding transmembrane proteins (TMEMs) in tumor and PBMC samples derived from ccRCC patients \[[@CR20]\]. TMEM protein family is characterized by a presence of putative transmembrane domains, as predicted by *in silico* methods, but limited functional data describing their detailed involvement in malignant transformation is available \[[@CR29]\].

Majority of ccRCC deregulated TMEMs were assigned, according to Singer's classification, as type 3 transmembrane proteins characterized by multiple transmembrane domains in a single polypeptide chain \[[@CR50]\]. This group was represented by TMEM61, TMEM30B, TMEM116 and TMEM45B down-regulated in ccRCC tumors and up-regulated TMEM22 (SLC35G2) and TMEM45A. TMEM61 belongs to TMEM61 protein family of unknown function. TMEM30B, predicted member of CDC50/LEM3 family of transcription regulators, facilitates a positive regulation of protein exit from endoplasmic reticulum in a cell \[[@CR60], [@CR61]\]. Its' down-regulation was reported in advanced and recurrent samples of meningioma \[[@CR11]\]. Similarly, we found more pronounced down-regulation in less differentiated tumors in our data set. TMEM116 showed tertiary structure similarity to human B2-adrenergic G protein-coupled receptor (GPCR) and human A2A adenosine receptor, found functionally deregulated in other cancer types and associated with tumor invasiveness and evasion of immune system \[[@CR62]--[@CR64]\]. Here we found *TMEM116* expression to be a potential independent predictor of overall survival, as shown by Cox regression, with hazard ratio with each 2-fold increase of *TMEM116* expression equal to 0.554. Cellular localization of the four down-regulated TMEMs was predicted as cytoplasmic, with TMEM116 to be likely of endoplasmic reticulum origin.

The up-regulated TMEM22 and TMEM45A encoded proteins were predicted to localize in endoplasmic reticulum. TMEM22 contains a domain similar to E.coli multidrug-resistance antiporter Emre, while TMEM45A (together with TMEM45B) was assigned to DUF716 protein family of unknown function in humans (Fig. [6](#Fig6){ref-type="fig"}). TMEM22 (SLC35G2) encodes a member G2 protein of solute carrier family 35, a polytopic transmembrane protein found in Golgi apparatus, endosomes and lysosomes \[[@CR65], [@CR66]\] possibly involved in nucleoside-sugar transport \[[@CR67]\]. Differential regulation in *SLC35G2* expression in intrahepatic cholangiocarcinoma \[[@CR68]\] and promoter hypermethylation of *SLC35G2* in melanoma were previously reported \[[@CR69]\]. Dobashi *et al.* found up-regulation of *SLC35G2* in Caki-1 and Caki-2 RCC cell lines and tumor samples; additionally, siRNA silencing of *SLC35G2* diminished cell growth in those cell lines, suggesting its potential involvement in cancer progression and development \[[@CR29]\]. Here, we also observe up-regulation of *SLC35G2* expression in our tumor set. Additionally, we find *SLC35G2* expression to be up-regulated in PBMCs collected from patients a year post-nephrectomy, as compared to PBMCs of healthy volunteers. This finding is very promising, although it requires additional conformation in an independent cohort.Fig. 6Predicted topologies of TMEMs. Signal sequences are in orange, transmembrane domains in green, functional domains derived from Pfam database in violet. All structures were generated using Localizome server

TMEM45A is a substrate for ubiquitin ligase and therefore can be degraded in proteasome \[[@CR70]\], similarly to TMEM45B, which interacts with ubiquitin-conjugating enzyme E2G 2 \[[@CR71]\]. Lee *et al.* observed that progression of ductal carcinoma in situ to invasive breast cancer in xenograft models increased dramatically when *TMEM45A* expression was suppressed \[[@CR72]\]. *TMEM45B* down-regulation was detected in squamous lung cell carcinoma, likely due to increased expression of miRNA targeting *TMEM45B* gene \[[@CR73]\]. Paulo *et al.* suggests *TMEM45B* regulation by *ERG* and *ETV1* transcription factors in prostate cancer cell lines \[[@CR74]\]. *TMEM45B* interacts with tubulointerstitial nephritis antigen (TINAG), which is thought to be involved in FAK/PI3K/Akt-mediated apoptosis \[[@CR75]\]. *TINAG* expression is also down-regulated in ccRCC, as shown by microarray experiments \[[@CR17]\]. We found that expression decrease of *TMEM45B* may be associated with organ-confined tumors, as shown by *t*-test.

Two proteins: TMEM213 and TMEM207 were assigned to transmembrane protein type 1a with a cleavable signal sequence \[[@CR50]\]. Both *TMEM213* and *TMEM207* genes were the most down-regulated in our ccRCC sample set. TMEM213 was predicted to be localized in ER and *in silico* analyses demonstrated existence of TMEM213 protein family with unknown function. TMEM207, with predicted cytoplasmic localization, showed a limited homology to Stannin (SNN), likely involved in mitochondria-mediated apoptosis \[[@CR76], [@CR77]\]. Although hierarchical clustering showed that down-regulation of both *TMEM213* and *TMEM207* genes, together with *TMEM72* and *TMEM116* could characterize more advanced ccRCC tumors, these observations require additional confirmation.

TMEM72, classified as a type 2 transmembrane protein, is predicted to be localized in mitochondria, with no similarities to known proteins. We found that strong *TMEM72* down-regulation could be associated with metastases, as revealed by the *t*-test and univariate and multivariate logistic regression. Similar trend is observed in more advanced tumors, as showed by hierarchical clustering.

Previously RTP3 (TMEM7) was classified as type NT transmembrane protein with ER retention signal, is predicted to function in endoplasmic reticulum (ER) membrane \[[@CR78], [@CR79]\]. RTP3 showed similarity to zf-3CxxC transcription regulators family, previously reported to be involved in renal cell carcinoma \[[@CR80], [@CR81]\]. Zhou *et al.* show that down-regulation or inactivation of *RTP3* was detected in 85 % of primary hepatocellular carcinomas and in 33 % of hepatocellular carcinoma cell lines, likely due to promoter hypermethylation \[[@CR82]\]. Although *RTP3* was significantly down-regulated in our tumor set, we did not observe any relevance of this down-regulation in respect to clinical and molecular tumor characteristics.

Interestingly, five of analyzed TMEMs were predicted to have ER membrane localization signals. Endoplasmic reticulum stress has a profound effect on cancer cell proliferation and survival in almost all types of cancer, including RCC \[[@CR62]\]. Duivenvoorden *et al.* found that endoplasmic reticulum protein -- ERp46 -- expression is elevated in ccRCC \[[@CR83]\]. Moreover, von Roemeling and colleagues report that inhibition of aberrant stearoyl-CoA desaturase 1 (SCD1) expression attenuates cell proliferation and induces apoptosis in ccRCC cells via the induction of endoplasmic reticulum stress response signaling \[[@CR84]\]. Although our findings require further validation, we show that TMEM proteins predicted to be localized in ER (i.e., SLC35G2, TMEM45A, TMEM45B, TMEM116, TMEM207 and TMEM213) can be potentially involved in ccRCC pathogenesis.

Conclusions {#Sec14}
===========

The massive down-regulation of expression of TMEM family members suggests their significant involvement in the pathogenesis of ccRCC. We found that down-regulation of all the TMEMs is most pronounced in advanced tumors and linked their deregulation to metastatic tumors, high Fuhrman grade and disease course. Topology and localization analysis classified majority of the TMEMs as type 3 and type 1 transmembrane proteins, with predicted localization in endoplasmic reticulum, prominently, supporting the involvement of ER proteins in ccRCC pathogenesis.

Additional files {#Sec15}
================

Additional file 1: Table S2.Clinical characteristics. Detailed clinical characteristics of patients involved in the study at the time of nephrectomy. Additional file 2: Table S3.Follow-up characteristics. Detailed characteristics of patients' follow-up. Time to progression -- time from nephrectomy to the latest follow-up (in months) or to the follow-up where progression occurred. Time to death -- time from nephrectomy to the latest follow-up (in months) or to the death date. In 'Progression' and 'Death' columns 0 means no progression or death (censored case), 1 means that the disease progressed (type of progression is summarized in 'Type of progression' column) or patient died from the disease. N/A -- data not available. Additional file 3: Table S1.Primer sequences used for qPCR TMEM expression measurements. Additional file 4: Figure S1.TMEM expression in metastatic and non-metastatic tumors. Average log~2~ relative expression data in each sample group ± standard error of mean is shown in each chart. FC -- fold-change. *n* -- number of samples. M0 -- non-metastatic ccRCC. M1 -- metastatic ccRCC tissues. q -- p-values adjusted for multiple comparisons using Benjamini-Hochberg correction. Additional file 5: Figure S2.TMEM expression in tumors at early and late stage of the disease, as assessed by TNM staging system. Average log~2~ relative expression data in each sample group ± standard error of mean is shown in each chart. FC -- fold-change. *n* -- number of samples. pT1/pT2 -- organ-confined tumors, as assessed by TNM staging system. pT3/pT4 -- advanced tumors, as assessed by TNM staging system. q -- p-values adjusted for multiple comparisons using Benjamini-Hochberg correction. Additional file 6: Figure S3.TMEM expression in tumors comprised of well differentiated or undifferentiated cells, as assessed by Fuhrman grading system. Average log~2~ relative expression data in each sample group ± standard error of mean is shown in each chart. FC -- fold-change. *n* -- number of samples. G1/G2 -- low Fuhrman grade samples. G3/G4 -- high Furhman grade samples. q -- p-values adjusted for multiple comparisons using Benjamini-Hochberg correction. Additional file 7: Table S4.Colocalization of topology and function prediction for TMEM213 at Metaserver Genesilico gateway . Colocalization of topology and function prediction for TMEM213 at Metaserver Genesilico gateway. TM helices were superimposed to the results from PSORT II and Localizome.
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